https://t.co/D1SuPcqOyj "In conclusion, our results show that improved anti-cancer efficacy can be achieved by co-targeting the AR axis and fat oxidation via CPT1A, which may have clinical implications, especially in the mCRPC setting."
https://t.co/D1SuPcqOyj "Lastly, using a xenograft mouse model, we have observed decreased tumor growth with a systemic combination treatment of enzalutamide and ranolazine."
https://t.co/D1SuPcqOyj "To better understand the clinical implications of these findings, we have evaluated fat oxidation inhibitors (etomoxir, ranolazine and perhexiline) in combination with enzalutamide in PCa cell models."
https://t.co/D1SuPcqgIL "This results in increased androgen receptor (AR) action and increased sensitivity to the anti-androgen enzalutamide."
https://t.co/D1SuPcqOyj "Mechanistically, we have found that decreased CPT1A expression is associated with decreased AKT content and activation, likely driven by a breakdown of membrane phospholipids and activation of the INPP5K phosphatase."
https://t.co/D1SuPcqgIL "Since lipid oxidation is stimulated by androgens, we have evaluated the synergistic effects of combining CPT1A inhibition and anti-androgen therapy."
Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/D1SuPcqOyj
RT @darioT_: Decoding #tumor promotion by recognizing the basilar nature of pro-tumorigenic mediators: a question of #biochemistry https://…
Decoding #tumor promotion by recognizing the basilar nature of pro-tumorigenic mediators: a question of #biochemistry https://t.co/hmynVjUzOl
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP... https:…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP... https:…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP... https:…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP... https:…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP... https:…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP... https:…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP... https:…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP... https:…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP #oncotarg…
RT @OncotargetACD: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade https://t.co/JP16L8PcVP... https:…